TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.

Natalie Y L Ngoi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.